Elevated Red Blood Cell Distribution Width as a Simple Prognostic Factor in Patients with Symptomatic Multiple Myeloma

Table 3

Multivariate analysis for progression-free survival.

	HR	95% CI	𝑃
Age at diagnosis (year)	0.99	0.93–1.05	0.691
ECOG (≥2)	1.48	0.63–3.51	0.373
Cytogenetic risk (high)	4.12	1.63–10.41	0.003
B2MG (mg/L)	1.09	0.99–1.20	0.071
Albumin (<3.5 g/dL)	0.82	0.31–2.17	0.690
LDH (>normal)	1.35	0.56–3.26	0.499
Hemoglobin (>10 g/dL)	0.67	0.28–1.61	0.365
Calcium (>normal)	2.20	0.54–9.03	0.272
Induction with novel agents*	0.34	0.14–0.81	0.014
ASCT	0.96	0.28–3.25	0.945
High-RDW (>14.5%)	3.21	1.24–8.32	0.016

∗Induction with bortezomib, thalidomide, or lenalidomide.
HR: hazard ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group; B2MG: 𝛽2-microglobulin; LDH: lactate dehydrogenase; ASCT: autologous stem cell transplantation; RDW: red blood cell distribution width.